GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Phreesia Inc (NYSE:PHR) » Definitions » Beneish M-Score

Phreesia (Phreesia) Beneish M-Score : -3.36 (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Phreesia Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.36 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Phreesia's Beneish M-Score or its related term are showing as below:

PHR' s Beneish M-Score Range Over the Past 10 Years
Min: -3.36   Med: -2.73   Max: -2.18
Current: -3.36

During the past 7 years, the highest Beneish M-Score of Phreesia was -2.18. The lowest was -3.36. And the median was -2.73.


Phreesia Beneish M-Score Historical Data

The historical data trend for Phreesia's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phreesia Beneish M-Score Chart

Phreesia Annual Data
Trend Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Beneish M-Score
Get a 7-Day Free Trial -2.73 -2.49 -2.18 -3.24 -3.36

Phreesia Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.24 -3.51 -3.55 -3.22 -3.36

Competitive Comparison of Phreesia's Beneish M-Score

For the Health Information Services subindustry, Phreesia's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phreesia's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Phreesia's Beneish M-Score falls into.



Phreesia Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Phreesia for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.995+0.528 * 0.9372+0.404 * 1.8431+0.892 * 1.2684+0.115 * 0.8421
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7724+4.679 * -0.279303-0.327 * 1.4074
=-3.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jan24) TTM:Last Year (Jan23) TTM:
Total Receivables was $64.9 Mil.
Revenue was 95.005 + 91.619 + 85.83 + 83.845 = $356.3 Mil.
Gross Profit was 63.231 + 60.68 + 55.529 + 52.848 = $232.3 Mil.
Total Current Assets was $195.7 Mil.
Total Assets was $370.3 Mil.
Property, Plant and Equipment(Net PPE) was $17.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $29.5 Mil.
Selling, General, & Admin. Expense(SGA) was $226.9 Mil.
Total Current Liabilities was $110.1 Mil.
Long-Term Debt & Capital Lease Obligation was $5.5 Mil.
Net Income was -30.646 + -31.941 + -36.767 + -37.531 = $-136.9 Mil.
Non Operating Income was -1.035 + -0.047 + 0.05 + -0.042 = $-1.1 Mil.
Cash Flow from Operations was -3.078 + -6.31 + -9.331 + -13.659 = $-32.4 Mil.
Total Receivables was $51.4 Mil.
Revenue was 76.586 + 73.103 + 67.867 + 63.354 = $280.9 Mil.
Gross Profit was 48.622 + 45.771 + 40.44 + 36.81 = $171.6 Mil.
Total Current Assets was $262.4 Mil.
Total Assets was $370.1 Mil.
Property, Plant and Equipment(Net PPE) was $22.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $25.3 Mil.
Selling, General, & Admin. Expense(SGA) was $231.6 Mil.
Total Current Liabilities was $79.0 Mil.
Long-Term Debt & Capital Lease Obligation was $3.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(64.863 / 356.299) / (51.394 / 280.91)
=0.182047 / 0.182955
=0.995

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(171.643 / 280.91) / (232.288 / 356.299)
=0.611025 / 0.651947
=0.9372

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (195.684 + 17.168) / 370.326) / (1 - (262.441 + 22.239) / 370.057)
=0.425231 / 0.230713
=1.8431

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=356.299 / 280.91
=1.2684

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(25.304 / (25.304 + 22.239)) / (29.487 / (29.487 + 17.168))
=0.532234 / 0.632022
=0.8421

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(226.934 / 356.299) / (231.647 / 280.91)
=0.63692 / 0.824631
=0.7724

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.534 + 110.119) / 370.326) / ((3.074 + 79.039) / 370.057)
=0.312301 / 0.221893
=1.4074

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-136.885 - -1.074 - -32.378) / 370.326
=-0.279303

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Phreesia has a M-score of -3.36 suggests that the company is unlikely to be a manipulator.


Phreesia Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Phreesia's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Phreesia (Phreesia) Business Description

Traded in Other Exchanges
Address
1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, USA, 19803
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
Executives
Balaji Gandhi officer: Chief Financial Officer PHREESIA, INC., 1521 CONCORD PIKE, SUITE 301, PMB 221, WILMINGTON DE 19803
Allison C Hoffman officer: General Counsel & Secretary 315 EAST 68TH STREET, NEW YORK NY 10065
Amy Beth Vanduyn officer: SVP, Human Resources C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Chaim Indig director, officer: Chief Executive Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Michael J. Davidoff officer: See Remarks C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
David Linetsky officer: SVP, Life Sciences C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Evan Roberts officer: Chief Operating Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Janet Gunzburg officer: Principal Accounting Officer BANKRATE, INC., 477 MADISON AVENUE, SUITE 430, NEW YORK NY 10022
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
Gillian Munson director C/O XO GROUP INC., 195 BROADWAY, 25TH FLOOR, NEW YORK NY 10007
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Randy Rasmussen officer: Chief Financial Officer PHREESIA, INC., 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC 27601
Ramin Sayar director 305 MAIN STREET, REDWOOD CITY CA 94063
Michael Weintraub director C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Edward L Cahill 10 percent owner C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 200, WALTHAM MA 02453